Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion capecitabine, please make sure that you also read the package insert for these. CATALOG SHEET · PACKAGE INSERT · SDS SHEET · BAR CODES · WHOLESALER ITEM NUMBERS · STORAGE REQUIREMENTS · RETURN GOODS. In depth information on Camptosar (irinotecan) for treatment of colorectal cancer. spacer. Camptosar (irinotecan) Product Information For Health Care Professionals CAMPTOSAR – Package Insert.
|Genre:||Health and Food|
|Published (Last):||26 January 2015|
|PDF File Size:||19.37 Mb|
|ePub File Size:||16.34 Mb|
|Price:||Free* [*Free Regsitration Required]|
Rashes have also been reported but did not result in discontinuation of treatment. Early and late forms of diarrhea can occur. Omit dose until resolved to baseline, then 1 dose level. Patients at Particular Risk: Several published guidelines for handling and disposal of anticancer agents are available.
Two multicenter, randomized, clinical studies further support the use of packahe given by the once-everyweek dosage schedule in patients with metastatic colorectal cancer whose disease has recurred or progressed following prior 5-FU therapy.
Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. All dose modifications should be based on the worst preceding toxicity.
Institute antibiotic therapy if patients camptsoar ileus, fever, or severe neutropenia. Mammalian cells cannot efficiently repair these double-strand breaks. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
Overview of Adverse Events Gastrointestinal: Maximum concentrations of the active metabolite SN are generally seen within 1 hour following the end of a minute infusion of irinotecan. SN is approximately times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. Deaths from cwmptosar cause within 60 days of first study treatment were captosar for 3 2. Long-term carcinogenicity studies with irinotecan were not conducted.
Camptosar Product Information
Deaths potentially related to treatment occurred in 2 0. Other drugs should not be added to the infusion solution. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. The majority of responses were observed within the first two courses of therapy, but camptozar did occur in later courses of treatment one response was observed after the eighth course.
At the start of each cycle of therapy, patients completed a questionnaire consisting of 30 questions, such as “Did pain interfere with daily campotsar
HIGHLIGHTS OF PRESCRIBING INFORMATION
Grade 3—4 neutropenia was experienced by 54 SN is formed from irinotecan by carboxylesterase-mediated cleavage of the inserh bond between the camptothecin moiety and the dipiperidino side chain. SN is approximately times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. Study 5 was a multicenter study that enrolled patients from 30 institutions. There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal.
Monitor patients with diarrhea and give fluid and electrolytes as insedt.
Camptosar Full Prescribing
The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined. The use of gloves is recommended. A new cycle of therapy should not begin until the toxicity has recovered to NCI grade 1 or less.
Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. The results as summarized in Table 4 are based on patients’ worst post-baseline scores. A total of patients with metastatic colorectal packwge whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase 3 studies: Omit dose until resolved to baseline, then 2 dose levels.
One of these patients died of neutropenic sepsis without fever.
Rates were also similar in patients with cancer of the colon or cancer of the rectum and in patients with single and multiple metastatic sites. In these same studies, patients with baseline serum total bilirubin levels of 1. Patients with baseline serum total bilirubin levels of 1. Refrigeration of admixtures using 0.
Late diarrhea can be life threatening and should be treated promptly with loperamide. The results of the individual studies are shown in Table Pacjage in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted.